Table 4.
Psychological test scores and CCL24 expression for participants in their 60s 1.
| 60s Group | Baseline | Follow-Up | Change | ||||
|---|---|---|---|---|---|---|---|
| Active | Placebo | Active | Placebo | Active | Placebo | p Value 2 | |
| WMS-1 3 | 13.5 (0.8) | 13.4 (0.8) | 11.3 (0.6) | 10.2 (0.7) | −2.3 (0.9) | −3.2 (0.6) | 0.31 |
| WMS-2 3 | 12.1 (0.8) | 12.7 (0.6) | 11.2 (0.6) | 9.2 (0.6) | −0.9 (0.7) | −3.4 (0.5) | 0.048 * |
| ADAS | 9.5 (0.8) | 7.6 (0.7) | 8.1 (0.7) | 6.4 (0.7) | −1.4 (0.6) | −1.2 (0.9) | 0.47 |
| SF-36 (PCS) | 48.6 (1.3) | 49.6 (1.0) | 52.1 (0.4) | 48.0 (2.1) | 3.4 (1.4) | −1.6 (1.5) | 0.08 ## |
| SF-36 (MCS) | 53.3 (1.6) | 51.0 (1.6) | 52.1 (1.4) | 51.6 (1.0) | −1.1 (1.2) | 0.6 (1.6) | 0.30 |
| BDI | 9.4 (1.2) | 8.9 (1.1) | 6.6 (0.9) | 8.6 (0.7) | −2.8 (0.8) | −0.3 (1.1) | 0.14 # |
| CCL24 post/pre | - | - | - | - | 0.86 (0.07) | 1.09 (0.09) | 0.14 # |
1 Data are represented by Ave (SEM). Significant deterioration in the placebo group at the follow-up test (p < 0.05, by Student’s two-tailed t-test); 2 To evaluate the effect of ACS on the protection of cognitive decline, data from the two groups (active and placebo) were analyzed by a one-tailed t-test; * p < 0.05, ## shows a trend towards significance (p < 0.1), # shows a weak trend towards significance (p < 0.2); 3 We utilized story A in the baseline test and story B in the follow-up test. Story B is relatively more difficult than story A.